PL4028002T3 - Przeciwnowotworowe połączenie chidamidu i celekoksybu - Google Patents

Przeciwnowotworowe połączenie chidamidu i celekoksybu

Info

Publication number
PL4028002T3
PL4028002T3 PL19944886.1T PL19944886T PL4028002T3 PL 4028002 T3 PL4028002 T3 PL 4028002T3 PL 19944886 T PL19944886 T PL 19944886T PL 4028002 T3 PL4028002 T3 PL 4028002T3
Authority
PL
Poland
Prior art keywords
chidamide
celecoxib
cancer combination
cancer
combination
Prior art date
Application number
PL19944886.1T
Other languages
English (en)
Inventor
Jia-Shiong Chen
Mu-Hsuan Yang
Cheng-Han Chou
Yi-Hong Wu
Sz-Hao Chu
Ye-Su CHAO
Chia-Nan Chen
Original Assignee
Great Novel Therapeutics Biotech & Medicals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Great Novel Therapeutics Biotech & Medicals Corporation filed Critical Great Novel Therapeutics Biotech & Medicals Corporation
Publication of PL4028002T3 publication Critical patent/PL4028002T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19944886.1T 2019-09-11 2019-09-11 Przeciwnowotworowe połączenie chidamidu i celekoksybu PL4028002T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/105421 WO2021046765A1 (en) 2019-09-11 2019-09-11 An anticancer combination of chidamide and celecoxib

Publications (1)

Publication Number Publication Date
PL4028002T3 true PL4028002T3 (pl) 2026-03-30

Family

ID=74865995

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19944886.1T PL4028002T3 (pl) 2019-09-11 2019-09-11 Przeciwnowotworowe połączenie chidamidu i celekoksybu

Country Status (10)

Country Link
EP (1) EP4028002B1 (pl)
JP (2) JP7869573B2 (pl)
KR (1) KR102908068B1 (pl)
CN (1) CN114786672B (pl)
AU (1) AU2019465985B2 (pl)
BR (1) BR112022004471A2 (pl)
ES (1) ES3057788T3 (pl)
MX (1) MX2022002856A (pl)
PL (1) PL4028002T3 (pl)
WO (1) WO2021046765A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322171B (zh) * 2022-08-30 2023-03-17 深圳微芯生物科技股份有限公司 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物
CN120965570A (zh) * 2024-10-29 2025-11-18 成都苑东生物制药股份有限公司 西达本胺晶型i及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103833626B (zh) * 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TR201900059A2 (tr) * 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem

Also Published As

Publication number Publication date
AU2019465985A1 (en) 2022-04-28
EP4028002A1 (en) 2022-07-20
CN114786672B (zh) 2024-07-12
JP2022547555A (ja) 2022-11-14
BR112022004471A2 (pt) 2022-05-31
EP4028002A4 (en) 2023-06-14
EP4028002B1 (en) 2025-12-17
MX2022002856A (es) 2022-03-25
EP4028002C0 (en) 2025-12-17
JP7869573B2 (ja) 2026-06-03
KR20220061179A (ko) 2022-05-12
JP2024105304A (ja) 2024-08-06
WO2021046765A1 (en) 2021-03-18
CN114786672A (zh) 2022-07-22
AU2019465985B2 (en) 2024-05-02
CA3153597A1 (en) 2021-03-18
KR102908068B1 (ko) 2026-01-05
ES3057788T3 (en) 2026-03-04

Similar Documents

Publication Publication Date Title
IL282775A (en) Selection of improved tumor reactive t-cells
EP3874764A4 (en) TEXT ANNOTATION OF ACOUSTIC EFFECTS
IL259102A (en) Non-invasive physiological quantification of stress levels
EP3746071A4 (en) GCN2 INHIBITORS AND THEIR USES
EP3353156A4 (en) AUTOPALMITOYLATION INHIBITORS OF THE TEAD TRANSCRIPTION FACTOR
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
PL4393545T3 (pl) Nowe zastosowania pochodnych piperydynylo-indolowych
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
IL258997B (en) Honey-cannabinoid therapeutic composition
DK3283107T3 (da) Sammensætninger omfattende en kombination af ipilimumab og nivolumab
DK3713554T3 (da) Doseringsanvisninger for vidofludimus til behandling af kroniske inflammatoriske og/eller autoimmunsygdomme
PL3394259T3 (pl) Kompozycje i sposoby zmniejszania ekspresji tau
DK4335517T3 (da) Indgivelse og dosering af diaminofenothiaziner
EP3314503A4 (en) SIMULATION OF AN APPLICATION
DK3182962T3 (da) Compositions and uses of amidine derivatives
PT3645518T (pt) Síntese de omecamtiv mecarbil
IL281938A (en) Stable semaglutide compositions and uses thereof
DK3355041T3 (da) Strækbar touchpad af den kapacitive type
LT3448846T (lt) Indazolų sintezė
PL3411021T3 (pl) Nowe zastosowanie kombinacji sakubitrylu i walsartanu
HUE049331T2 (hu) Indazolok szintézise
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
SI3573620T1 (sl) Sestavki za zdravljenje hipertenzije
IL281230A (en) Formulations of cycloserine compounds and applications thereof
EP3589734A4 (en) REGULATION OF GENE EXPRESSION BY CLIVING BY RNASE P MODULATED BY APTAMER